-Kaohsiung Medical University –

Kaohsiung Medical University (KMU) achieved a major breakthrough in innovation at the 22nd National Innovation Awards 2025, securing a total of 13 honors, including three Academic Research Innovation Awards and ten Clinical Innovation Awards. The award-winning achievements span diverse fields such as new drug development, smart healthcare, advanced medical devices, artificial intelligence (AI), and clinical care, fully demonstrating KMU’s long-term strength in biomedical research, clinical translation, and medical innovation, and underscoring its role as a key driver of biomedical innovation in southern Taiwan.

The National Innovation Awards are among Taiwan’s most prestigious honors in the biomedical and health sectors. The evaluation criteria emphasize technological innovation, clinical or market application potential, and tangible contributions to industry and society. Leveraging its comprehensive healthcare system and robust clinical service capacity, KMU is able to respond swiftly to frontline clinical needs, transforming medical challenges into innovative R&D solutions. Through interdisciplinary integration and clinical validation mechanisms, the university accelerates technology maturation and implementation, fostering a clinical needs–driven medical innovation ecosystem.

KMU stated that the 13 award-winning projects are built upon extensive clinical experience accumulated across its integrated healthcare system and strong interdisciplinary collaboration. Several of these innovations have already completed multi-country patent portfolios. Moving forward, KMU will continue to deepen partnerships with industry, accelerate technology translation and clinical implementation, and build a globally competitive medical innovation ecosystem—creating greater medical value and industrial opportunities. 

▲Kaohsiung Medical University receives recognition with 13 National Innovation Awards; group photo of the award-winning teams